CAPS
MCID: CTS005
MIFTS: 43

Catastrophic Antiphospholipid Syndrome (CAPS)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Catastrophic Antiphospholipid Syndrome

MalaCards integrated aliases for Catastrophic Antiphospholipid Syndrome:

Name: Catastrophic Antiphospholipid Syndrome 20 58 70
Catastrophic Antiphospholipid Antibody Syndrome 20
Cryopyrin-Associated Periodic Syndromes 70
Thrombotic Storm 20
Catastrophic Aps 58
Caps 58

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D68.6
Orphanet 58 ORPHA464343
UMLS 70 C2316212 C3662487

Summaries for Catastrophic Antiphospholipid Syndrome

GARD : 20 Catastrophic antiphospholipid syndrome (CAPS) is a rare form of antiphospholipid syndrome (APS). In CAPS multiple blood clots form throughout the body over a short period of time (usually within a week). CAPS is a medical emergency, as clots can cause life-threatening multi- organ failure. The cause of CAPS is unknown. A widely accepted explanation is that it is caused by a combination of gene mutations (making one more susceptible to CAPS) and an environmental trigger, such as an infection, trauma, or surgery.

MalaCards based summary : Catastrophic Antiphospholipid Syndrome, also known as catastrophic antiphospholipid antibody syndrome, is related to thrombotic microangiopathy and heparin-induced thrombocytopenia. An important gene associated with Catastrophic Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Trandolapril and Captopril have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and skin, and related phenotypes are homeostasis/metabolism and mortality/aging

Wikipedia : 73 Catastrophic antiphospholipid syndrome (CAPS), also known as Asherson's syndrome, is a rare autoimmune... more...

Related Diseases for Catastrophic Antiphospholipid Syndrome

Diseases related to Catastrophic Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
# Related Disease Score Top Affiliating Genes
1 thrombotic microangiopathy 31.3 F3 ADAMTS13
2 heparin-induced thrombocytopenia 30.8 F3 CD40LG
3 antiphospholipid syndrome 30.7 SERPINE1 MTHFR F5 F3 CFH CD40LG
4 hemolytic-uremic syndrome 30.6 F3 CFH ADAMTS13
5 thrombotic thrombocytopenic purpura 30.6 F3 CFH APOH ADAMTS13
6 hepatic infarction 30.5 F3 APOH
7 splenic infarction 30.5 F3 APOH
8 hemolytic anemia 30.4 F3 CFH CD40LG APOH ADAMTS13
9 disseminated intravascular coagulation 30.4 SERPINE1 F5 F3 ADAMTS13
10 purpura 30.2 PROC F3 APOH ADAMTS13
11 severe pre-eclampsia 30.2 F5 CFH APOH
12 anuria 30.2 F3 ADAMTS13
13 coronary thrombosis 30.2 SERPINE1 F3
14 acquired hemophilia 30.2 F5 F3
15 mixed connective tissue disease 30.1 CD40LG APOH ADAMTS13
16 malignant hypertension 30.1 CFH ADAMTS13
17 ischemic colitis 30.1 SERPINE1 F5 APOH
18 hemolytic uremic syndrome, atypical 1 30.0 F3 CFH ADAMTS13
19 syphilis 29.9 CD40LG APOH
20 myelitis 29.8 MTHFR APOH
21 branch retinal artery occlusion 29.8 MTHFR F3 APOH
22 systemic lupus erythematosus 29.8 SERPINE1 HLA-DRB4 F3 CD40LG APOH ADAMTS13
23 central retinal vein occlusion 29.6 MTHFR F5 F3 APOH
24 venous insufficiency 29.6 SERPINE1 MTHFR F5
25 kidney disease 29.5 SERPINE1 MTHFR F3 CFH
26 intracranial thrombosis 29.5 MTHFR F5 F3 APOH
27 purpura fulminans 29.5 PROC F5 F3 APOH
28 pre-eclampsia 29.5 SERPINE1 MTHFR F5 F3 APOH
29 budd-chiari syndrome 29.5 MTHFR F5 F3 APOH
30 placenta disease 29.5 MTHFR F5 F3 APOH
31 retinal artery occlusion 29.4 SERPINE1 MTHFR F5 APOH
32 homocysteinemia 29.4 SERPINE1 MTHFR F5 APOH
33 hellp syndrome 29.3 SERPINE1 MTHFR F5 F3 CFH APOH
34 retinal vein occlusion 29.2 SERPINE1 MTHFR F5 F3 APOH
35 pulmonary embolism 29.1 SERPINE1 PROC MTHFR F5 F3 APOH
36 patent foramen ovale 29.0 SERPINE1 MTHFR F5 F3 APOH
37 thrombophilia 28.9 SERPINE1 PROC MTHFR F5 F3 APOH
38 protein c deficiency 28.9 SERPINE1 PROC MTHFR F5 APOH
39 protein s deficiency 28.8 PROC MTHFR F5 F3 APOH
40 vascular disease 28.8 SERPINE1 MTHFR F5 F3 CD40LG APOH
41 thrombophilia due to thrombin defect 28.7 SERPINE1 PROC MTHFR F5 F3 APOH
42 thrombocytopenia 28.6 SERPINE1 PROC MTHFR F5 F3 CFH
43 myocardial infarction 28.5 SERPINE1 MTHFR F5 F3 CFH CD40LG
44 thrombosis 28.4 SERPINE1 PROC MTHFR F5 F3 CD40LG
45 thrombophlebitis 28.4 SERPINE1 PROC MTHFR F5 F3 APOH
46 lupus erythematosus 10.6
47 respiratory failure 10.5
48 adult respiratory distress syndrome 10.5
49 autoimmune disease 10.4
50 vasculitis 10.4

Graphical network of the top 20 diseases related to Catastrophic Antiphospholipid Syndrome:



Diseases related to Catastrophic Antiphospholipid Syndrome

Symptoms & Phenotypes for Catastrophic Antiphospholipid Syndrome

MGI Mouse Phenotypes related to Catastrophic Antiphospholipid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ADAMTS13 APOH CD40LG CFH F3 F5
2 mortality/aging MP:0010768 9.32 ADAMTS13 APOH CD40LG CFH CRLS1 F3

Drugs & Therapeutics for Catastrophic Antiphospholipid Syndrome

Drugs for Catastrophic Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 706)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trandolapril Approved Phase 4 87679-37-6 5484727
2
Captopril Approved Phase 4 62571-86-2 44093
3
Interferon beta-1b Approved Phase 4 145155-23-3
4
Colestipol Approved Phase 4 26658-42-4
5
Ezetimibe Approved Phase 4 163222-33-1 150311
6
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
7
Lopinavir Approved Phase 4 192725-17-0 92727
8
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
11
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Clarithromycin Approved Phase 4 81103-11-9 84029
15
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
16
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
17
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
18
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
21
Insulin aspart Approved Phase 4 116094-23-6 16132418
22
Pramlintide Approved, Investigational Phase 4 151126-32-8
23
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
24
Insulin lispro Approved Phase 4 133107-64-9
25
Insulin detemir Approved Phase 4 169148-63-4 5311023
26
Mefenamic acid Approved Phase 4 61-68-7 4044
27
Silodosin Approved Phase 4 160970-54-7
28
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
29
Iron Approved Phase 4 7439-89-6 23925 29936
30
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
31
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
32
Levetiracetam Approved Phase 4 102767-28-2 441341
33
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
34
Atorvastatin Approved Phase 4 134523-00-5 60823
35
Apixaban Approved Phase 4 503612-47-3 10182969
36
Cefdinir Approved Phase 4 91832-40-5 6915944
37
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
38
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
39
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
40
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
41
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
42
Sulbactam Approved Phase 4 68373-14-8
43
Sultamicillin Approved, Investigational Phase 4 76497-13-7
44
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
45
Pantoprazole Approved Phase 4 102625-70-7 4679
46
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
47
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
48
Ceftibuten Approved, Investigational Phase 4 97519-39-6 5282241 5282242
49
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
50
Rebamipide Approved, Investigational Phase 4 90098-04-7

Interventional clinical trials:

(show top 50) (show all 798)
# Name Status NCT ID Phase Drugs
1 Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS) Unknown status NCT00252317 Phase 4 Captopril and Trandolapril;Captopril Test Dose and Trandolapril
2 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
3 A Double-blind, Randomized, Placebo Controlled Clinical Trial on Comparing Escitalopram and Duloxetine add-on for Negative Symptoms in Schizophrenic Subjects With Neuregulin-1 (NRG1) Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
4 Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
5 Clinical and Radiographic Evaluation of Light Cured Resin Modified Calcium Silicate Versus Light Cured Calcium Hydroxide in Indirect Pulp Treatment of Primary Molars Unknown status NCT03791255 Phase 4 Calcium silicate liner;Calcium hydroxide liner
6 The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis Unknown status NCT00963222 Phase 4 vitamin A;placebo
7 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
8 Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients Unknown status NCT01417273 Phase 4 Drug: placebo
9 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
10 Postoperative Pain After Application of Silver Diamine Fluoride and Glass Ionomer Versus Glass Ionomer Alone Following Minimal Caries Removal Technique in Asymptomatic Young Permanent Teeth With Deep Caries. A Randomized Pilot Study. Unknown status NCT03568474 Phase 4 Silver Diamine Fluoride;Glass Ionomer
11 The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients Unknown status NCT01414972 Phase 4 Vitamin A;placebo
12 The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients Unknown status NCT01407211 Phase 4
13 Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial Unknown status NCT02201641 Phase 4
14 The Impact of Omega-3 Supplementation on Acylation Stimulating Protein(ASP), Retinol-binding Protein 4 (RBP4) and Lipocalin-2 (LCN2) Gene Expression of ASP Receptor (C5L2) in WBC of Patient With Diabetes Type 2 Unknown status NCT01478776 Phase 4
15 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
16 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
17 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
18 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
19 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Unknown status NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
20 Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study. Unknown status NCT01509274 Phase 4
21 A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation Unknown status NCT03542721 Phase 4 DA-5515;Placebo of DA-5515
22 Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults Unknown status NCT03400735 Phase 4 Cefdinir 300Mg Capsule
23 Impact of Combined Ezetimibe and Atorvastatin Therapy on Coronary Thin-cap Fibroatheroma As Assessed by Optical Coherence Tomography Unknown status NCT02588235 Phase 4 Ezetimibe and Atorvastatin;Atorvastatin
24 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
25 The Effect of n-3 Fatty Acid Supplementation on the Expression of Sirt-1, Adiponectin Receptor 1 (AdipoR1) & Adiponectin Receptor 2 (AdipoR2) Genes of PBMC and Circulatory Levels of Resistin,Monocyte Chemotactic Protein (MCP-1) and Adiponectin of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
26 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
27 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
28 A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence Completed NCT00785616 Phase 4
29 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
30 Exercise and Phytoestrogens: a Synergistic Effect on Factors Predisposing to CVD in Postmenopausal Women Completed NCT01048606 Phase 4
31 Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazorac .1% Gel or Vehicle Gel Completed NCT00145106 Phase 4 Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
32 Treatment of Vitamin D Insufficiency Completed NCT00933244 Phase 4
33 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial Completed NCT00847600 Phase 4
34 A Double Blind, Placebo-Controlled, Pilot Study to Estimate the Efficacy and Tolerability of Twice Daily Promiseb Topical Cream in Pediatric Subjects With Cradle Cap (Seborrheic Dermatitis) Completed NCT01214434 Phase 4
35 A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator Completed NCT00546676 Phase 4 Telithromycin
36 A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia Completed NCT00035347 Phase 4 IV azithromycin;ceftriaxone;oral azithromycin;IV levofloxacin;oral levofloxacin
37 Cathflo Activase (Alteplase) Pediatric Study (CAPS) Completed NCT00307580 Phase 4 Cathflo Activase (Alteplase)
38 Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
39 The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea Completed NCT01598012 Phase 4 Ayurved Siriraj Prasaplai with or without mefenamic acid;Placebo with or without mefenamic acid
40 Make up for the Epinephrine Autoinjector: Effect on Its Use by Untrained Users Completed NCT01217138 Phase 4
41 Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With Coronary Artery Disease Completed NCT02382471 Phase 4
42 Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With Coronary Artery Disease Completed NCT02117960 Phase 4
43 Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With Cardiovascular Disease. Completed NCT02092584 Phase 4
44 To Evaluate the Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine as Pulpotomy Medicament in Patients With Pulpitis. Completed NCT04773886 Phase 4 Mineral trioxide aggregate;Biodentine
45 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
46 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
47 Immediate and Delayed Loading of 4.1 mm and 4.8 mm Implants in the Posterior Mandible & Maxilla: A Controlled Randomized Study of Single or 2-4 Unit Restorations Loaded Immediately After Surgery or Four Weeks After Surgery Completed NCT00782171 Phase 4
48 A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
49 CaP Cement is Equivalent to Iliac Bone Graft in Filling of Large Metaphyseal Defects: A 2 Year Prospective Randomised Study on Distal Radius Osteotomies Completed NCT02827006 Phase 4
50 Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography Completed NCT00700037 Phase 4 high-dose atorvastatin;low-dose atorvastatin

Search NIH Clinical Center for Catastrophic Antiphospholipid Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


anakinra

Genetic Tests for Catastrophic Antiphospholipid Syndrome

Anatomical Context for Catastrophic Antiphospholipid Syndrome

MalaCards organs/tissues related to Catastrophic Antiphospholipid Syndrome:

40
Liver, Bone, Skin, Endothelial, Colon, Bone Marrow, Heart

Publications for Catastrophic Antiphospholipid Syndrome

Articles related to Catastrophic Antiphospholipid Syndrome:

(show top 50) (show all 519)
# Title Authors PMID Year
1
Catastrophic antiphospholipid syndrome presented as ruptured papillary muscle during puerperium in a patient with systemic lupus erythematosus. 61
33736518 2021
2
[Spontaneous adrenal hematomas. Retrospective analysis of 20 cases from a tertiary center]. 61
33775473 2021
3
Markers of complement activation in plasma during quiescent phases in catastrophic antiphospholipid syndrome patients. 61
33649771 2021
4
Massive Right Ventricular Thrombus Secondary to Catastrophic Antiphospholipid Syndrome. 61
31985720 2021
5
Pediatric Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab. 61
33142067 2021
6
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It? 61
33535377 2021
7
A rare case of catastrophic antiphospholipid syndrome triggered by estrogen-containing oral contraceptives in a patient with double heterozygous factor V Leiden and prothrombin G20210A mutations. 61
33621390 2021
8
[New aspects of therapeutic plasma exchange in critical care medicine]. 61
33513650 2021
9
Successful Management of Catastrophic Thrombotic Storm in a Young Boy: A Case Report From Northern India. 61
33560088 2021
10
Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus. 61
33081592 2021
11
Update on the Use of Intravenous Immunoglobulin in Pregnancy. 61
33386311 2021
12
Conservative Management of Catastrophic Antiphospholipid Syndrome-Related Skin Necrosis: A Case Report. 61
33208666 2020
13
Viral infections and their relationship with catastrophic antiphospholipid syndrome: a possible pathogenic mechanism of severe COVID-19 thrombotic complications. 61
32506640 2020
14
Case of catastrophic antiphospholipid syndrome presenting as neuroretinitis and vaso-occlusive retinopathy. 61
33298003 2020
15
Catastrophic antiphospholipid syndrome post-Epstein-Barr virus infection: a case report. 61
33358683 2020
16
Catastrophic Thrombotic Storm. 61
33434868 2020
17
Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab. 61
32722806 2020
18
Catastrophic Antiphospholipid Syndrome: Skin, Eye and Brain Involvement. 61
33186069 2020
19
Polyunsaturated fatty acid biosynthesis pathway and genetics. implications for interindividual variability in prothrombotic, inflammatory conditions such as COVID-19✰,✰✰,★,★★. 61
33038834 2020
20
Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus: a case-based review. 61
33140653 2020
21
Hematological Manifestations among Patients with Rheumatic Diseases. 61
33221805 2020
22
Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm. 61
33222114 2020
23
"APS pregnancy - The offspring". 61
32752918 2020
24
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. 61
32733003 2020
25
Digital Ischemia as the Initial Presentation of Catastrophic Antiphospholipid Syndrome. 61
33268294 2020
26
The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome? 61
32788116 2020
27
16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. 61
32819183 2020
28
Extensive catastrophic thromboses from elevation of factor VIII. 61
32952985 2020
29
Probable catastrophic antiphospholipid syndrome secondary to chronic myelomonocytic leukaemia in an adult patient and a mini review. 61
32605525 2020
30
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia. 61
32532610 2020
31
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. 61
32681497 2020
32
Aortitis in the setting of catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus. 61
32517572 2020
33
Catastrophic antiphospholipid syndrome refractory to high-dose intravenous immunoglobulin responsive to therapeutic plasma exchange. 61
32762580 2020
34
Successful treatment of catastrophic antiphospholipid syndrome with therapeutic plasma exchange: a case report. 61
31537477 2020
35
Catastrophic antiphospholipid syndrome: is life-long anticoagulation therapy required? 61
32107665 2020
36
Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban. 61
32223511 2020
37
Successful secondary thromboprophylaxis with direct oral anticoagulants for a patient with catastrophic antiphospholipid syndrome: A case report. 61
32590766 2020
38
Sudden Cardiac Arrest as the First Manifestation in a Patient with Catastrophic Antiphospholipid Syndrome. 61
32161219 2020
39
Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19. 61
32463794 2020
40
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. 61
32252584 2020
41
Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. 61
31853731 2020
42
Retiform purpura: Workup and therapeutic considerations in select conditions. 61
31479690 2020
43
A Rare Case of Catastrophic Antiphospholipid Antibody Syndrome: A Case Report and Review of Traditional Cardiovascular Risk Factors Implicated in Disease Occurrence. 61
32274279 2020
44
["STILL IS NOT ENOUGH" - WHAT IS THE DIFFERENTIAL DIAGNOSIS AND THE WORKUP WHEN THE FERRITIN LEVEL IS EXTREMELY HIGH?] 61
32186785 2020
45
Catastrophic antiphospholipid syndrome - a case report of a highly fatal disease. 61
32409401 2020
46
Treatment of Vascular Thrombosis in Antiphospholipid Syndrome: An Update. 61
31994163 2020
47
Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome? 61
33224503 2020
48
Catastrophic Antiphospholipid Syndrome-Associated Nephropathy in a Systemic Lupus Erythematosus Patient Without Lupus Nephritis. 61
31609535 2020
49
A "Catastrophic" Heparin-Induced Thrombocytopenia. 61
32328108 2020
50
COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association? 61
33328777 2020

Variations for Catastrophic Antiphospholipid Syndrome

Expression for Catastrophic Antiphospholipid Syndrome

Search GEO for disease gene expression data for Catastrophic Antiphospholipid Syndrome.

Pathways for Catastrophic Antiphospholipid Syndrome

GO Terms for Catastrophic Antiphospholipid Syndrome

Cellular components related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 SERPINE1 PROC F5 F3 CFH CD40LG
2 cell surface GO:0009986 9.46 F3 CD40LG APOH ADAMTS13
3 extracellular space GO:0005615 9.23 SERPINE1 PROC F5 F3 CFH CD40LG

Biological processes related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.5 SERPINE1 F5 APOH
2 blood coagulation GO:0007596 9.46 PROC F5 F3 ADAMTS13
3 positive regulation of blood coagulation GO:0030194 9.37 SERPINE1 APOH
4 negative regulation of fibrinolysis GO:0051918 9.26 SERPINE1 APOH
5 negative regulation of blood coagulation GO:0030195 9.13 SERPINE1 PROC APOH
6 hemostasis GO:0007599 8.92 PROC F5 F3 ADAMTS13

Sources for Catastrophic Antiphospholipid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....